Could second-trimester medical abortion be offered as a day service? Assessing the feasibility of a 1-day outpatient procedure using pooled data from six clinical studies



      Current service delivery models for second-trimester medical abortion typically include routine inpatient admission and overnight stays. To assess the feasibility of a day-service model, we evaluated outpatient administration of abortion medications and analyzed the proportion of clients who could avoid an overnight stay. We also examined additional key elements of medical abortion care to evaluate the practicality of this model.

      Study design

      We pooled data from six clinical studies of second-trimester medical abortion conducted by Gynuity over the past 10 years. We include 868 individuals receiving mifepristone–misoprostol abortion between 13 and 22 weeks’ gestation.


      At 8 h post misoprostol initiation, 309/521 (59.3%) participants at 13-18 weeks' gestation had a successful abortion; by 10 h, 382/521 (73.3%) were successful. Taking the mifepristone at home lowered neither the efficacy of the method nor satisfaction with the experience. Nonphysician providers played a significant role in the provision of care. Needed interventions were relatively rare; serious complications were very rare.


      Our findings support the provision of second-trimester medical abortion in a day-clinic setting, especially at ≤18 weeks' gestation. Such a model could increase access to quality care in many settings.


      Second-trimester medical abortion can safely and effectively be offered as a day service. Nonphysician providers are well suited to provide the majority of care. Developing guidelines for a 1-day model could increase access to quality care in many settings worldwide.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Winikoff B.
        • Westhoff C.
        Fifteen years: looking back and looking forward.
        Contraception. 2015; 92: 177-178
        • World Health Organization
        Safe abortion: technical and policy guidance for health systems.
        WHO, Geneva2012
        • American College of Obstetricians and Gynecologists
        Practice bulletin no. 143: medical management of first-trimester abortion.
        Obstet Gynecol. 2014; 123: 676-692
        • Wildschut H.
        • Both M.I.
        • Medema S.
        • Thomee E.
        • Wildhagen M.F.
        • Kapp N.
        Medical methods for mid-trimester termination of pregnancy.
        Cochrane Database Syst Rev. 2011; 1CD005216
        • Shaw K.A.
        • Topp N.J.
        • Shaw J.G.
        • Blumenthal P.D.
        Mifepristone-misoprostol dosing interval and effect on induction abortion times: a systematic review.
        Obstet Gynecol. 2013; 121: 1335-1347
        • Bygdeman M.
        • Gemzell-Danielsson K.
        An historical overview of second trimester abortion methods.
        Reprod Health Matters. 2008; 16: 196-204
      1. Br Med J. 1976; 1: 1373-1376
        • World Health Organization Task Force on the Use of Prostaglandins for the Regulation of Fertility
        Prostaglandins and abortion. III. Comparison of single intra-amniotic injections of 15-methyl prostaglandin F2alpha and prostaglandin F2alpha for termination of second-trimester pregnancy: an international multicenter study.
        Am J Obstet Gynecol. 1977; 129: 601-606
        • Kapp N.
        • Borgatta L.
        • Stubblefield P.
        • Vragovic O.
        • Moreno N.
        Mifepristone in second-trimester medical abortion: a randomized controlled trial.
        Obstet Gynecol. 2007; 110: 1304-1310
        • Louie K.S.
        • Chong E.
        • Tsereteli T.
        • Avagyan G.
        • Abrahamyan R.
        • Winikoff B.
        Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia.
        Eur J Contracept Reprod Health Care. 2017; 22: 76-80
        • Abbas D.F.
        • Blum J.
        • Ngoc N.T.
        • Nga N.T.
        • Chi H.T.
        • Martin R.
        • et al.
        Simultaneous administration compared with a 24-hour mifepristone–misoprostol interval in second-trimester abortion: a randomized controlled trial.
        Obstet Gynecol. 2016; 128: 1077-1083
        • Dabash R.
        • Chelli H.
        • Hajri S.
        • Shochet T.
        • Raghavan S.
        • Winikoff B.
        A double-blind randomized controlled trial of mifepristone or placebo prior to buccal misoprostol for abortion at 14-21 weeks of pregnancy.
        Int J Gynaecol Obstet. 2015; 130: 40-44
        • Ngoc N.T.
        • Shochet T.
        • Raghavan S.
        • Blum J.
        • Nga T.N.
        • Minh N.T.
        • et al.
        Mifepristone and misoprostol compared to misoprostol alone for mid-trimester abortion between 14-21 weeks' LMP.
        Obstet Gynecol. 2011; 118: 601-608
        • Gemzell-Danielsson K.
        • Lalitkumar S.
        Second trimester medical abortion with mifepristone–misoprostol and misoprostol alone: a review of methods and management.
        Reprod Health Matters. 2008; 16: 162-172
        • Lalitkumar S.
        • Bygdeman M.
        • Gemzell-Danielsson K.
        Mid-trimester induced abortion: a review.
        Hum Reprod Update. 2007; 13: 37-52
        • Ashok P.W.
        • Templeton A.
        • Wagaarachchi P.T.
        • Flett G.M.M.
        Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases.
        Contraception. 2004; 69: 51-58
        • Grossman D.
        • Blanchard K.
        • Blumenthal P.
        Complications after second trimester surgical and medical abortion.
        Reprod Health Matters. 2008; 16: 173-182
        • Constant D.
        • Harries J.
        • Malaba T.
        • Myer L.
        • Patel M.
        • Petro G.
        • et al.
        Clinical outcomes and women's experiences before and after the introduction of mifepristone into second-trimester medical abortion services in South Africa.
        PLoS One. 2016; 11e0161843
        • World Health Organization
        Health worker roles in providing safe abortion care and post-abortion contraception.
        World Health Organization, Geneva2015
        • Elul B.
        • Hajri S.
        • Ngoc N.N.
        • Ellertson C.
        • Slama C.B.
        • Pearlman E.
        • et al.
        Can women in less-developed countries use a simplified medical abortion regimen?.
        Lancet. 2001; 357: 1402-1405
        • Ngoc N.N.
        • Nhan V.Q.
        • Blum J.
        • Mai T.T.P.
        • Durocher J.
        • Winikoff B.
        Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam.
        BJOG. 2004; 111: 814-819
        • Kawonga M.
        • Blanchard K.
        • Cooper D.
        • Cullingowrth L.
        • Dickson K.
        • Harrison T.
        • et al.
        Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa.
        J Fam Plann Reprod Health Care. 2008; 34: 159-164
        • Karki C.
        • Pokharel H.
        • Kushwaha A.
        • Manandhar D.
        • Bracken H.
        • Winikoff B.
        Acceptability and feasibility of medical abortion in Nepal.
        Int J Gynaecol Obstet. 2009; 106: 39-42
        • Mentula M.
        • Suhonen S.
        • Heikinheimo O.
        One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy--a randomized trial.
        Hum Reprod. 2011; 26: 2690-2697
        • United Nations Department of Economic and Social Affairs Population Division
        World abortion policies 2013.
        United Nations, New York, USA2013